RCT | Low-dose olanzapine enhances appetite & weight gain in chemotherapy patients

Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentaries:

Olanzapine to Prevent Chemotherapy-Related Anorexia in Newly Diagnosed Patients With Advanced Cancers – The ASCO Post

Low-dose olanzapine improves appetite in chemotherapy patients – MDedge

Commentary on Twitter

This trial is as good as it gets ⭐️⭐️⭐️⭐️⭐️

✅Patient centered supportive care trial
✅Inexpensive medication
✅Conducted in a LMIC
✅Clinically relevant endpoint
✅ Randomized/double-blinded study
✅Potential to immediately change practicehttps://t.co/3nRrFJaS20

Kudos!

— Manni Mohyuddin (@ManniMD1) March 29, 2023